Myriad Genetics (MYGN) Other Accumulated Expenses (2014 - 2020)

Myriad Genetics has disclosed Other Accumulated Expenses across 7 years of filings, most recently posting $22.4 million for Q2 2020.

• In Q2 2020, Other Accumulated Expenses rose 146.15% year-over-year to $22.4 million; the TTM figure through Jun 2020 stood at $22.4 million (up 146.15% YoY), while the FY2020 annual figure was $22.4 million, up 146.15% from the prior year.
• Other Accumulated Expenses climbed to $22.4 million in Q2 2020, from $4.3 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for MYGN reached as high as $22.4 million in Q2 2020 and fell as low as $4.3 million in Q1 2020.
• The 5-year median for Other Accumulated Expenses is $13.8 million (2016), against an average of $13.3 million.
• The widest YoY moves for Other Accumulated Expenses: up 146.15% in 2020, down 80.09% in 2020.
• A 5-year view of Other Accumulated Expenses shows it stood at $13.7 million in 2016, then climbed by 13.87% to $15.6 million in 2017, then grew by 13.46% to $17.7 million in 2018, then tumbled by 53.67% to $8.2 million in 2019, then soared by 173.17% to $22.4 million in 2020.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $22.4 million, $4.3 million, and $8.2 million for Q2 2020, Q1 2020, and Q4 2019 respectively.